Maintenance DFMO Increases Survival in High Risk Neuroblastoma

High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (...

Descripción completa

Detalles Bibliográficos
Autores principales: Sholler, Giselle L. Saulnier, Ferguson, William, Bergendahl, Genevieve, Bond, Jeffrey P., Neville, Kathleen, Eslin, Don, Brown, Valerie, Roberts, William, Wada, Randal K., Oesterheld, Javier, Mitchell, Deanna, Foley, Jessica, Parikh, Nehal S., Eshun, Francis, Zage, Peter, Rawwas, Jawhar, Sencer, Susan, Pankiewicz, Debra, Quinn, Monique, Rich, Maria, Junewick, Joseph, Kraveka, Jacqueline M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160434/
https://www.ncbi.nlm.nih.gov/pubmed/30262852
http://dx.doi.org/10.1038/s41598-018-32659-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160434/
https://www.ncbi.nlm.nih.gov/pubmed/30262852
http://dx.doi.org/10.1038/s41598-018-32659-w

Ejemplares similares